Locally Advanced Non-Small Cell Lung Cancer
Conditions
Interventions
Chemoradiotherapy: Combination of weekly carboplatin plus nab-paclitaxel with concurrent thoracic radiotherapy for a total 60Gy at 2Gy/fraction/day 5times weekly for 30 times. Consolidation thera
Sponsors
Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Cytologically or histologically documented NSCLC. 2)Untreated Stage IIIA or IIIB disease 3)Unresectable 4)V20 under 35 percent and an approval of a radiotherapist by CT simulation based on the restriction of this protcol before registration. 5)Have measurable lesion 6)Patient aged 20-74 years old at the time of consent. 7)Eastern Cooperative Oncology Group Performance Status(ECOG PS) 0 or 1 8)Organ functions are met for this study within two week before study entry. 9)With signed an informed consent document
Exclusion criteria
Exclusion criteria: 1) With opposite hilar lymph nodes metastases 2) With interstitial lung disease, lung fibrosis 3) SVC syndrome 4) With active infection 5) With active double cancer 6) With other serious disease condition (bleeding, cardiac diseases, poorly controlled diabetes,etc.) 7) Clinically significant allergy 8) Patients with steroid treatment 9) Uncontrolled psychiatric disease 10) Pregnancy or lactating patients 11) Positive serum HBs antigen 12) Others
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| phase I:determine the recommended dose phase II:2year survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| phase I:safety, response rate, progression free survival,overall survival, completion rate of chemoradiotherapy phase II:safety, response rate, progression free survival, overall survival, completion rate of chemoradiotherapy | — |
Countries
Japan
Contacts
Public ContactYuko Kawano
Kyushu Univiersity Hospital Respiratory Medicine
Outcome results
None listed